Avalo Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Avalo Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Avalo Therapeutics Inc
Rating: 1.68091675
Author: Trendlyne DVM scores

about

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

15.75 -0.50 (-3.08%)

364.60% Gain from 52W Low

249.6K

XNAS Volume

XNAS 23 Jan, 2026 4:30 PM (EST)

Not Eligible

Expensive Valuation

8.7 / 100

Technically Neutral

58.6 / 100

1Yr Price target upside is 118%

8 analysts

Avalo Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Avalo Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

364.60% Gain from 52W Low

SWOT Analysis

Avalo Therapeutics Inc Live Price Chart